HHS Accountability Project publication

Unforgivable Hypocrisy From FDA’s Career CDER Leadership

David Gortler

The same career FDA bureaucrat who loudly crowed about “following the science” to discredit President Trump has approved a failed Alzheimer’s drug.

Articles

Forbes / July 19, 2021

Separate Payments for Abortion Services and Other Changes in HHS’s Proposed Insurance Regulations

Rachel N. Morrison

A new rule proposed by HHS would, among other changes, reverse Trump-era insurance regulations requiring separate billing and collection of payments for certain abortion services.

Articles

Revisiting Harris Funeral Homes’ Compelling Government Interest Analysis After Fulton

Rachel N. Morrison

United States Supreme Court exterior

After Fulton, the Sixth Circuit’s compelling interest analysis in Harris Funeral Homes cannot stand. Courts cannot credit the alleged compelling government interest of non-discrimination by ignoring the constitutional guarantee of free exercise.

Articles

National Review Online / July 8, 2021

Why Unanimity Was So Important in the Fulton Case

Roger Severino

With its 9-0 ruling in favor of the Fulton plaintiffs, the Supreme Court is saying people with sincere faith-informed understandings of social issues that cut against the grain of secularist thought aren’t to be treated as bigots, and government needs to back off.

Articles

National Review Online / June 18, 2021

Breaking: EEOC Chairwoman Unilaterally Issues Gender Guidelines

Roger Severino

Charlotte Burrows, chairwoman of the Equal Employment Opportunity Commission (EEOC), posted a guidance document purporting to apply Bostock v. Clayton County, which redefined Title VII’s prohibitions on discrimination “because of sex” to include sexual orientation and transgender status in certain contexts.

Articles

National Review Online / June 15, 2021

FDA’s New CDER Director Grants Approval of Yet Another Expensive, Scientifically Questionable Drug … More…

David Gortler

Since the FDA operates without external oversight, it’s not possible to hold the agency accountable for bad approval decisions that ultimately place taxpayers on the hook for hundreds of billions of dollars via Medicare Part B program.

Articles

Forbes / June 11, 2021

Why Would Planned Parenthood Care About Donor Disclosure Laws When HHS Is Handing Them Millions…

Rachel N. Morrison

Planned Parenthood is directly implicated in litigation currently before the Supreme Court on a donor disclosure law, but is mysteriously silent on the issue.

Articles

The Federalist / June 3, 2021

EPPC Scholar Comment at HHS COVID-19 Health Equity Task Force Meeting

Rachel N. Morrison

EPPC Policy Analyst Rachel N. Morrison offered comment at HHS’s COVID-19 Health Equity Task Force meeting, urging the task force “to ensure that your efforts to promote equity do not encourage or enable illegal discrimination.”

Articles, Testimony

Publications / May 28, 2021

Drug Quality “Trumps” Drug Pricing

David Gortler

There is an enormous national security risk to relying on geopolitical adversaries like China for America’s life-saving drugs. This is similar to the risk that both the Republican and Democrat parties recognized with respect to our energy supplies, where a renewed focus on domestic production enabled the U.S. to become a net oil exporter by 2019. The move to energy independence created good paying jobs for thousands of Americans.

Articles

Forbes / May 25, 2021

Biden’s HHS Chooses Ideology Over Science on Transgender Issues

Roger Severino

HHS Secretary Xavier Becerra and Assistant Secretary of Health Dr. Rachel Levine seem to want to intimidate scientists, health care providers and insurers into bowing to gender identity politics without having to explain their actions to the public.

Articles

Newsweek / May 20, 2021

EPPC Scholar Comment Opposing Proposed Title X Rule on Abortion Funding

Rachel N. Morrison

EPPC Policy Analyst Rachel N. Morrison submitted a public comment to the U.S. Department of Health and Human Services (HHS) objecting to HHS’s proposed Title X rule that would funnel millions of taxpayer dollars to abortion providers by undoing a Trump-era regulation that ensured separation between Title X funded programs and abortion activities.

Articles

Publications / May 17, 2021

China Is at War with the FDA. Guess Who’s Winning.

David Gortler

China is allowing only those tested for COVID-19 and vaccinated with its proprietary vaccines to enter their country. This represents a problem when it comes to the regulation of drugs for American consumers: China’s vaccine entry requirements make it nearly impossible for the FDA to fully staff regulatory operational activity in China.  

Articles

Forbes / April 23, 2021